The significance of toll-like receptors in human diseases

Allergologia et Immunopathologia

Volumn 37, Issue 5, 2009, Pages 252-263

  Montero Vega, M T ^a   de Andres Martin A ^b  

^a Servicio de Investigacion Agraria   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Innate immunity; Toll like receptors

Indexed keywords

TOLL LIKE RECEPTOR;

ADAPTIVE IMMUNITY; ALLERGY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNITY; CARCINOGENESIS; CELL ACTIVATION; CELLULAR DISTRIBUTION; EFFECTOR CELL; ENTERITIS; EPITHELIUM; GENE EXPRESSION REGULATION; HUMAN; IMMUNE DEFICIENCY; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INFECTION SENSITIVITY; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; MAST CELL; NEOPLASM; NONHUMAN; POLARIZATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TISSUE REGENERATION; TISSUE REPAIR;

ADAPTIVE IMMUNITY; AUTOIMMUNE DISEASES; DISEASE SUSCEPTIBILITY; EPITHELIUM; HUMANS; HYPERSENSITIVITY; IMMUNITY, INNATE; INFECTION; INFLAMMATION; NEOPLASMS; REGENERATION; TOLL-LIKE RECEPTORS;

EID: 70350267055     PISSN: 03010546     EISSN: 15781267     Source Type: Journal    
DOI: 10.1016/j.aller.2009.04.004     Document Type: Article

References (172)

1. Barton G.M. A calculated response: control of inflammation by the innate immune system. J Clin Invest 118 (2008) 413-420
2. Joffre O., Nolte M.A., Sporri R., and Reis e Sousa C. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol Rev 227 (2009) 234-247
3. Rakoff-Nahoum S., and Medzhitov R. Role of toll-like receptors in tissue repair and tumorigenesis. Biochemistry (Mosc) 73 (2008) 555-561
4. Chen K., Huang J., Gong W., Iribarren P., Dunlop N.M., and Wang J.M. Toll-like receptors in inflammation, infection and cancer. Int Immunopharmacol 7 (2007) 1271-1285
5. Atkinson T.J. Toll-like receptors, transduction-effector pathways, and disease diversity: evidence of an immunobiological paradigm explaining all human illness?. Int Rev Immunol 27 (2008) 255-281
6. Misch E.A., and Hawn T.R. Toll-like receptor polymorphisms and susceptibility to human disease. Clin Sci (Lond) 114 (2008) 347-360
7. Montero Vega M.T., and de Andres Martin A. Toll-like receptors: a family of innate sensors of danger that alert and drive immunity. Allergol Immunopathol (Madr) 36 (2008) 347-357
8. Ritter M., Mennerich D., Weith A., and Seither P. Characterization of Toll-like receptors in primary lung epithelial cells: strong impact of the TLR3 ligand poly(I:C) on the regulation of Toll-like receptors, adaptor proteins and inflammatory response. J Inflamm (Lond) 2 (2005) 16
9. Song J., and Abraham S.N. TLR-mediated immune responses in the urinary tract. Curr Opin Microbiol 11 (2008) 66-73
10. Gribar S.C., Richardson W.M., Sodhi C.P., and Hackam D.J. No longer an innocent bystander: epithelial toll-like receptor signaling in the development of mucosal inflammation. Mol Med 14 (2008) 645-659
11. Fritz J.H., Le Bourhis L., Magalhaes J.G., and Philpott D.J. Innate immune recognition at the epithelial barrier drives adaptive immunity: APCs take the back seat. Trends Immunol 29 (2008) 41-49
12. Neish A.S. Microbes in gastrointestinal health and disease. Gastroenterology 136 (2009) 65-80
13. Rakoff-Nahoum S., Paglino J., Eslami-Varzaneh F., Edberg S., and Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118 (2004) 229-241
14. Harris G., KuoLee R., and Chen W. Role of Toll-like receptors in health and diseases of gastrointestinal tract. World J Gastroenterol 12 (2006) 2149-2160
15. Michelsen K.S., and Arditi M. Toll-like receptors and innate immunity in gut homeostasis and pathology. Curr Opin Hematol 14 (2007) 48-54
16. Stenson W.F. Toll-like receptors and intestinal epithelial repair. Curr Opin Gastroenterol 24 (2008) 103-107
17. Cario E., Brown D., McKee M., Lynch-Devaney K., Gerken G., and Podolsky D.K. Commensal-associated molecular patterns induce selective toll-like receptor-trafficking from apical membrane to cytoplasmic compartments in polarized intestinal epithelium. Am J Pathol 160 (2002) 165-173
18. Ortega-Cava C.F., Ishihara S., Rumi M.A., Kawashima K., Ishimura N., Kazumori H., et al. Strategic compartmentalization of Toll-like receptor 4 in the mouse gut. J Immunol 170 (2003) 3977-3985
19. Abreu M.T., Thomas L.S., Arnold E.T., Lukasek K., Michelsen K.S., and Arditi M. TLR signaling at the intestinal epithelial interface. J Endotoxin Res 9 (2003) 322-330
20. Hornef M.W., Normark B.H., Vandewalle A., and Normark S. Intracellular recognition of lipopolysaccharide by toll-like receptor 4 in intestinal epithelial cells. J Exp Med 198 (2003) 1225-1235
21. Otte J.M., Cario E., and Podolsky D.K. Mechanisms of cross hyporesponsiveness to Toll-like receptor bacterial ligands in intestinal epithelial cells. Gastroenterology 126 (2004) 1054-1070
22. Furrie E., Macfarlane S., Thomson G., and Macfarlane G.T. Toll-like receptors-2, -3 and -4 expression patterns on human colon and their regulation by mucosal-associated bacteria. Immunology 115 (2005) 565-574
23. Lee J., Gonzales-Navajas J.M., and Raz E. The "polarizing-tolerizing" mechanism of intestinal epithelium: its relevance to colonic homeostasis. Semin Immunopathol 30 (2008) 3-9
24. Shibolet O., and Podolsky D.K. TLRs in the Gut. IV. Negative regulation of Toll-like receptors and intestinal homeostasis: addition by subtraction. Am J Physiol Gastrointest Liver Physiol 292 (2007) G1469-G1473
25. Gon Y. Toll-like receptors and airway inflammation. Allergol Int 57 (2008) 33-37
26. Wang Y., Bai C., Li K., Adler K.B., and Wang X. Role of airway epithelial cells in development of asthma and allergic rhinitis. Respir Med (2008)
27. Sha Q., Truong-Tran A.Q., Plitt J.R., Beck L.A., and Schleimer R.P. Activation of airway epithelial cells by toll-like receptor agonists. Am J Respir Cell Mol Biol 31 (2004) 358-364
28. Koff J.L., Shao M.X., Ueki I.F., and Nadel J.A. Multiple TLRs activate EGFR via a signaling cascade to produce innate immune responses in airway epithelium. Am J Physiol Lung Cell Mol Physiol (2008)
29. Holgate S.T. The epithelium takes centre stage in asthma and atopic dermatitis. Trends Immunol 28 (2007) 248-251
30. Into T., Kanno Y., Dohkan J., Nakashima M., Inomata M., Shibata K., et al. Pathogen recognition by Toll-like receptor 2 activates Weibel-Palade body exocytosis in human aortic endothelial cells. J Biol Chem 282 (2007) 8134-8141
31. Erridge C., Spickett C.M., and Webb D.J. Non-enterobacterial endotoxins stimulate human coronary artery but not venous endothelial cell activation via Toll-like receptor 2. Cardiovasc Res 73 (2007) 181-189
32. Breslin J.W., Wu M.H., Guo M., Reynoso R., and Yuan S.Y. Toll-like receptor 4 contributes to microvascular inflammation and barrier dysfunction in thermal injury. Shock 29 (2008) 349-355
33. Pegu A., Qin S., Fallert Junecko B.A., Nisato R.E., Pepper M.S., and Reinhart T.A. Human Lymphatic Endothelial Cells Express Multiple Functional TLRs. J Immunol 180 (2008) 3399-3405
34. Fitzner N., Clauberg S., Essmann F., Liebmann J., and Kolb-Bachofen V. Human skin endothelial cells can express all 10 TLR genes and respond to respective ligands. Clin Vaccine Immunol 15 (2008) 138-146
35. Qi H.Y., and Shelhamer J.H. Toll-like receptor 4 signaling regulates cytosolic phospholipase A2 activation and lipid generation in lipopolysaccharide-stimulated macrophages. J Biol Chem 280 (2005) 38969-38975
36. Yang C.S., Shin D.M., Lee H.M., Son J.W., Lee S.J., Akira S., et al. ASK1-p38 MAPK-p47phox activation is essential for inflammatory responses during tuberculosis via TLR2-ROS signalling. Cell Microbiol 10 (2008) 741-754
37. Zarember K.A., and Godowski P.J. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 168 (2002) 554-561
38. McCoy C.E., and O'Neill L.A. The role of toll-like receptors in macrophages. Front Biosci 13 (2008) 62-70
39. Ozato K., Tsujimura H., and Tamura T. Toll-like receptor signaling and regulation of cytokine gene expression in the immune system. Biotechniques (2002) 66-68 70, 72 passim
40. Chi D.S., Walker E.S., Hossler F.E., and Krishnaswamy G. Bacterial activation of mast cells. Methods Mol Biol 315 (2006) 383-392
41. Supajatura V., Ushio H., Nakao A., Akira S., Okumura K., Ra C., et al. Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J Clin Invest 109 (2002) 1351-1359
42. Varadaradjalou S., Feger F., Thieblemont N., Hamouda N.B., Pleau J.M., Dy M., et al. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells. Eur J Immunol 33 (2003) 899-906
43. Kulka M., Alexopoulou L., Flavell R.A., and Metcalfe D.D. Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3. J Allergy Clin Immunol 114 (2004) 174-182
44. Orinska Z., Bulanova E., Budagian V., Metz M., Maurer M., and Bulfone-Paus S. TLR3-induced activation of mast cells modulates CD8+ T-cell recruitment. Blood 106 (2005) 978-987
45. Dawicki W., and Marshall J.S. New and emerging roles for mast cells in host defence. Curr Opin Immunol 19 (2007) 31-38
46. Mortaz E., Redegeld F.A., Dunsmore K., Odoms K., Wong H.R., Nijkamp F.P., et al. Stimulation of cysteinyl leukotriene production in mast cells by heat shock and acetylsalicylic acid. Eur J Pharmacol 561 (2007) 214-219
47. Yamashita M., and Nakayama T. Progress in allergy signal research on mast cells: regulation of allergic airway inflammation through toll-like receptor 4-mediated modification of mast cell function. J Pharmacol Sci 106 (2008) 332-335
48. Nigo Y.I., Yamashita M., Hirahara K., Shinnakasu R., Inami M., Kimura M., et al. Regulation of allergic airway inflammation through Toll-like receptor 4-mediated modification of mast cell function. Proc Natl Acad Sci U S A 103 (2006) 2286-2291
49. Kikawada E., Bonventre J.V., and Arm J.P. Group V secretory PLA2 regulates TLR2-dependent eicosanoid generation in mouse mast cells through amplification of ERK and cPLA2alpha activation. Blood 110 (2007) 561-567
50. Qiao H., Andrade M.V., Lisboa F.A., Morgan K., and Beaven M.A. FcepsilonR1 and toll-like receptors mediate synergistic signals to markedly augment production of inflammatory cytokines in murine mast cells. Blood 107 (2006) 610-618
51. Muzio M., Bosisio D., Polentarutti N., D'Amico G., Stoppacciaro A., Mancinelli R., et al. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol 164 (2000) 5998-6004
52. Parker L.C., Whyte M.K., Dower S.K., and Sabroe I. The expression and roles of Toll-like receptors in the biology of the human neutrophil. J Leukoc Biol 77 (2005) 886-892
53. Hattermann K., Picard S., Borgeat M., Leclerc P., Pouliot M., and Borgeat P. The Toll-like receptor 7/8-ligand resiquimod (R-848) primes human neutrophils for leukotriene B4, prostaglandin E2 and platelet-activating factor biosynthesis. Faseb J 21 (2007) 1575-1585
54. Nagase H., Okugawa S., Ota Y., Yamaguchi M., Tomizawa H., Matsushima K., et al. Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. J Immunol 171 (2003) 3977-3982
55. Wong C.K., Cheung P.F., Ip W.K., and Lam C.W. Intracellular signaling mechanisms regulating toll-like receptor-mediated activation of eosinophils. Am J Respir Cell Mol Biol 37 (2007) 85-96
56. Lauzon N.M., Mian F., MacKenzie R., and Ashkar A.A. The direct effects of Toll-like receptor ligands on human NK cell cytokine production and cytotoxicity. Cell Immunol 241 (2006) 102-112
57. Hart O.M., Athie-Morales V., O'Connor G.M., and Gardiner C.M. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production. J Immunol 175 (2005) 1636-1642
58. Sawaki J., Tsutsui H., Hayashi N., Yasuda K., Akira S., Tanizawa T., et al. Type 1 cytokine/chemokine production by mouse NK cells following activation of their TLR/MyD88-mediated pathways. Int Immunol 19 (2007) 311-320
59. Boyd J.H., Divangahi M., Yahiaoui L., Gvozdic D., Qureshi S., and Petrof B.J. Toll-like receptors differentially regulate CC and CXC chemokines in skeletal muscle via NF-kappaB and calcineurin. Infect Immun 74 (2006) 6829-6838
60. Sukkar M.B., Xie S., Khorasani N.M., Kon O.M., Stanbridge R., Issa R., et al. Toll-like receptor 2, 3, and 4 expression and function in human airway smooth muscle. J Allergy Clin Immunol 118 (2006) 641-648
61. Miller L.S., and Modlin R.L. Toll-like receptors in the skin. Semin Immunopathol 29 (2007) 15-26
62. Kopp A., Buechler C., Neumeier M., Weigert J., Aslanidis C., Scholmerich J., et al. Innate Immunity and Adipocyte Function: Ligand-specific Activation of Multiple Toll-like Receptors Modulates Cytokine, Adipokine, and Chemokine Secretion in Adipocytes. Obesity (Silver Spring) 17 (2009) 648-656
63. Foti M., Granucci F., and Ricciardi-Castagnoli P. Dendritic cell interactions and cytokine production. Ernst Schering Res Found Workshop (2006) 61-80
64. Steinman R.M., and Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol 311 (2006) 17-58
65. Sato K., and Fujita S. Dendritic cells: nature and classification. Allergol Int 56 (2007) 183-191
66. Lee H.K., and Iwasaki A. Innate control of adaptive immunity: dendritic cells and beyond. Semin Immunol 19 (2007) 48-55
67. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 5 (2004) 987-995
68. Duez C., Gosset P., and Tonnel A.B. Dendritic cells and toll-like receptors in allergy and asthma. Eur J Dermatol 16 (2006) 12-16
69. Blander J.M. Coupling Toll-like receptor signaling with phagocytosis: potentiation of antigen presentation. Trends Immunol 28 (2007) 19-25
70. Watts C., Zaru R., Prescott A.R., Wallin R.P., and West M.A. Proximal effects of Toll-like receptor activation in dendritic cells. Curr Opin Immunol 19 (2007) 73-78
71. Goldman M. Translational mini-review series on Toll-like receptors: Toll-like receptor ligands as novel pharmaceuticals for allergic disorders. Clin Exp Immunol 147 (2007) 208-216
72. van Vliet S.J., den Dunnen J., Gringhuis S.I., Geijtenbeek T.B., and van Kooyk Y. Innate signaling and regulation of Dendritic cell immunity. Curr Opin Immunol 19 (2007) 435-440
73. Hochrein H., and O'Keeffe M. Dendritic cell subsets and toll-like receptors. Handb Exp Pharmacol (2008) 153-179
74. Liotta F., Frosali F., Querci V., Mantei A., Fili L., Maggi L., et al. Human immature myeloid dendritic cells trigger a TH2-polarizing program via Jagged-1/Notch interaction. J Allergy Clin Immunol 121 (2008) 1000-1005 e8
75. Benko S., Magyarics Z., Szabo A., and Rajnavolgyi E. Dendritic cell subtypes as primary targets of vaccines: the emerging role and cross-talk of pattern recognition receptors. Biol Chem (2008)
76. Visintin A., Mazzoni A., Spitzer J.H., Wyllie D.H., Dower S.K., and Segal D.M. Regulation of Toll-like receptors in human monocytes and dendritic cells. J Immunol 166 (2001) 249-255
77. Hoyne G.F., Le Roux I., Corsin-Jimenez M., Tan K., Dunne J., Forsyth L.M., et al. Serrate1-induced notch signalling regulates the decision between immunity and tolerance made by peripheral CD4(+) T cells. Int Immunol 12 (2000) 177-185
78. Pearce E.J., Kane C.M., and Sun J. Regulation of dendritic cell function by pathogen-derived molecules plays a key role in dictating the outcome of the adaptive immune response. Chem Immunol Allergy 90 (2006) 82-90
79. Perrigoue J.G., Marshall F., and Artis D. On the hunt for helminths: Innate immune cells in the recognition and response to helminth parasites. Cell Microbiol (2008)
80. Napolitani G., Rinaldi A., Bertoni F., Sallusto F., and Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 6 (2005) 769-776
81. Skokos D., and Nussenzweig M.C. CD8- DCs induce IL-12-independent Th1 differentiation through Delta 4 Notch-like ligand in response to bacterial LPS. J Exp Med 204 (2007) 1525-1531
82. Raymond T., Schaller M., Hogaboam C.M., Lukacs N.W., Rochford R., and Kunkel S.L. Toll-like receptors, Notch ligands, and cytokines drive the chronicity of lung inflammation. Proc Am Thorac Soc 4 (2007) 635-641
83. Sun J., Krawczyk C.J., and Pearce E.J. Suppression of Th2 cell development by Notch ligands Delta1 and Delta4. J Immunol 180 (2008) 1655-1661
84. Weaver C.T., Harrington L.E., Mangan P.R., Gavrieli M., and Murphy K.M. Th17: an effector CD4T cell lineage with regulatory T cell ties. Immunity 24 (2006) 677-688
85. Kato A., Favoreto Jr. S., Avila P.C., and Schleimer R.P. TLR3- and Th2 cytokine-dependent production of thymic stromal lymphopoietin in human airway epithelial cells. J Immunol 179 (2007) 1080-1087
86. Akdis C.A., Kussebi F., Pulendran B., Akdis M., Lauener R.P., Schmidt-Weber C.B., et al. Inhibition of T helper 2-type responses, IgE production and eosinophilia by synthetic lipopeptides. Eur J Immunol 33 (2003) 2717-2726
87. Sieling P.A., Chung W., Duong B.T., Godowski P.J., and Modlin R.L. Toll-like receptor 2 ligands as adjuvants for human Th1 responses. J Immunol 170 (2003) 194-200
88. Imanishi T., Hara H., Suzuki S., Suzuki N., Akira S., and Saito T. Cutting edge: TLR2 directly triggers Th1 effector functions. J Immunol 178 (2007) 6715-6719
89. Taylor R.C., Richmond P., and Upham J.W. Toll-like receptor 2 ligands inhibit TH2 responses to mite allergen. J Allergy Clin Immunol 117 (2006) 1148-1154
90. Mandron M., Aries M.F., Brehm R.D., Tranter H.S., Acharya K.R., Charveron M., et al. Human dendritic cells conditioned with Staphylococcus aureus enterotoxin B promote TH2 cell polarization. J Allergy Clin Immunol 117 (2006) 1141-1147
91. Vanden Eijnden S., Goriely S., De Wit D., Goldman M., and Willems F. Preferential production of the IL-12(p40)/IL-23(p19) heterodimer by dendritic cells from human newborns. Eur J Immunol 36 (2006) 21-26
92. Fitzgerald-Bocarsly P., Dai J., and Singh S. Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev 19 (2008) 3-19
93. Ito T., Kanzler H., Duramad O., Cao W., and Liu Y.J. Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells. Blood 107 (2006) 2423-2431
94. Cao W., and Liu Y.J. Innate immune functions of plasmacytoid dendritic cells. Curr Opin Immunol 19 (2007) 24-30
95. Biron C.A. Interferons alpha and beta as immune regulators - a new look. Immunity 14 (2001) 661-664
96. Dorn A., and Kippenberger S. Clinical application of CpG-, non-CpG-, and antisense oligodeoxynucleotides as immunomodulators. Curr Opin Mol Ther 10 (2008) 10-20
97. Fillatreau S., and Manz R.A. Tolls for B cells. Eur J Immunol 36 (2006) 798-801
98. Kabelitz D. Expression and function of Toll-like receptors in T lymphocytes. Curr Opin Immunol 19 (2007) 39-45
99. LaRosa D.F., Stumhofer J.S., Gelman A.E., Rahman A.H., Taylor D.K., Hunter C.A., et al. T cell expression of MyD88 is required for resistance to Toxoplasma gondii. Proc Natl Acad Sci U S A 105 (2008) 3855-3860
100. van Maren W.W., Jacobs J.F., de Vries I.J., Nierkens S., and Adema G.J. Toll-like receptor signalling on Tregs: to suppress or not to suppress?. Immunology 124 (2008) 445-452
101. Tabiasco J., Devevre E., Rufer N., Salaun B., Cerottini J.C., Speiser D., et al. Human effector CD8+ T lymphocytes express TLR3 as a functional coreceptor. J Immunol 177 (2006) 8708-8713
102. Kabelitz D., Wesch D., and Oberg H.H. Regulation of regulatory T cells: role of dendritic cells and toll-like receptors. Crit Rev Immunol 26 (2006) 291-306
103. Pasare C., and Medzhitov R. Toll-like receptors and acquired immunity. Semin Immunol 16 (2004) 23-26
104. Ruprecht C.R., and Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol 36 (2006) 810-816
105. Bernasconi N.L., Onai N., and Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 101 (2003) 4500-4504
106. Bourke E., Bosisio D., Golay J., Polentarutti N., and Mantovani A. The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood 102 (2003) 956-963
107. Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol 19 (2007) 3-10
108. Kluwe J., Mencin A., and Schwabe R.F. Toll-like receptors, wound healing, and carcinogenesis. J Mol Med 87 (2009) 125-138
109. Pevsner-Fischer M., Morad V., Cohen-Sfady M., Rousso-Noori L., Zanin-Zhorov A., Cohen S., et al. Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood 109 (2007) 1422-1432
110. Kim S., Takahashi H., Lin W.W., Descargues P., Grivennikov S., Kim Y., et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457 (2009) 102-106
111. Turvey S.E., and Hawn T.R. Towards subtlety: understanding the role of Toll-like receptor signaling in susceptibility to human infections. Clin Immunol 120 (2006) 1-9
112. Khor C.C., Chapman S.J., Vannberg F.O., Dunne A., Murphy C., Ling E.Y., et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 39 (2007) 523-528
113. Sebban H., and Courtois G. NF-kappaB and inflammation in genetic disease. Biochem Pharmacol 72 (2006) 1153-1160
114. Smahi A., Courtois G., Vabres P., Yamaoka S., Heuertz S., Munnich A., et al., The International Incontinentia Pigmenti (IP) Consortium. Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. Nature 405 (2000) 466-472
115. Zonana J., Elder M.E., Schneider L.C., Orlow S.J., Moss C., Golabi M., et al. A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO). Am J Hum Genet 67 (2000) 1555-1562
116. Doffinger R., Smahi A., Bessia C., Geissmann F., Feinberg J., Durandy A., et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat Genet 27 (2001) 277-285
117. Courtois G., Smahi A., Reichenbach J., Doffinger R., Cancrini C., Bonnet M., et al. A hypermorphic IkappaBalpha mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. J Clin Invest 112 (2003) 1108-1115
118. Picard C., Puel A., Bonnet M., Ku C.L., Bustamante J., Yang K., et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 299 (2003) 2076-2079
119. Day N., Tangsinmankong N., Ochs H., Rucker R., Picard C., Casanova J.L., et al. Interleukin receptor-associated kinase (IRAK-4) deficiency associated with bacterial infections and failure to sustain antibody responses. J Pediatr 144 (2004) 524-526
120. Enders A., Pannicke U., Berner R., Henneke P., Radlinger K., Schwarz K., et al. Two siblings with lethal pneumococcal meningitis in a family with a mutation in Interleukin-1 receptor-associated kinase 4. J Pediatr 145 (2004) 698-700
121. Chapel H., Puel A., von Bernuth H., Picard C., and Casanova J.L. Shigella sonnei meningitis due to interleukin-1 receptor-associated kinase-4 deficiency: first association with a primary immune deficiency. Clin Infect Dis 40 (2005) 1227-1231
122. Ku C.L., Picard C., Erdos M., Jeurissen A., Bustamante J., Puel A., et al. IRAK4 and NEMO mutations in otherwise healthy children with recurrent invasive pneumococcal disease. J Med Genet 44 (2007) 16-23
123. Weighardt H., and Holzmann B. Role of Toll-like receptor responses for sepsis pathogenesis. Immunobiology 212 (2007) 715-722
124. Hawn T.R., Dunstan S.J., Thwaites G.E., Simmons C.P., Thuong N.T., Lan N.T., et al. A polymorphism in Toll-interleukin 1 receptor domain containing adaptor protein is associated with susceptibility to meningeal tuberculosis. J Infect Dis 194 (2006) 1127-1134
125. Netea M.G., van der Graaf C., Van der Meer J.W., and Kullberg B.J. Toll-like receptors and the host defense against microbial pathogens: bringing specificity to the innate-immune system. J Leukoc Biol 75 (2004) 749-755
126. Gehring A.J., Rojas R.E., Canaday D.H., Lakey D.L., Harding C.V., and Boom W.H. The Mycobacterium tuberculosis 19-kilodalton lipoprotein inhibits gamma interferon-regulated HLA-DR and Fc gamma R1 on human macrophages through Toll-like receptor 2. Infect Immun 71 (2003) 4487-4497
127. Netea M.G., Sutmuller R., Hermann C., Van der Graaf C.A., Van der Meer J.W., van Krieken J.H., et al. Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells. J Immunol 172 (2004) 3712-3718
128. DiPerna G., Stack J., Bowie A.G., Boyd A., Kotwal G., Zhang Z., et al. Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis actor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptors. J Biol Chem 279 (2004) 36570-36578
129. Mitchell J.A., Ryffel B., Quesniaux V.F., Cartwright N., and Paul-Clark M. Role of pattern-recognition receptors in cardiovascular health and disease. Biochem Soc Trans 35 (2007) 1449-1452
130. Frantz S., Ertl G., and Bauersachs J. Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med 4 (2007) 444-454
131. Tabas I., Williams K.J., and Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 116 (2007) 1832-1844
132. Tobias P.S., and Curtiss L.K. Toll-like receptors in atherosclerosis. Biochem Soc Trans 35 (2007) 1453-1455
133. Schoneveld A.H., Hoefer I., Sluijter J.P., Laman J.D., de Kleijn D.P., and Pasterkamp G. Atherosclerotic lesion development and Toll like receptor 2 and 4 responsiveness. Atherosclerosis 197 (2008) 95-104
134. Curtiss L.K., and Tobias P.S. Emerging role of toll-like receptors in atherosclerosis. J Lipid Res (2008)
135. Strober W. Immunology. Unraveling gut inflammation. Science 313 (2006) 1052-1054
136. Yamamoto-Furusho J.K., and Podolsky D.K. Innate immunity in inflammatory bowel disease. World J Gastroenterol 13 (2007) 5577-5580
137. Pierik M., Joossens S., Van Steen K., Van Schuerbeek N., Vlietinck R., Rutgeerts P., et al. Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases. Inflamm Bowel Dis 12 (2006) 1-8
138. Obermeier F., Dunger N., Strauch U.G., Hofmann C., Bleich A., Grunwald N., et al. CpG motifs of bacterial DNA essentially contribute to the perpetuation of chronic intestinal inflammation. Gastroenterology 129 (2005) 913-927
139. Borm M.E., van Bodegraven A.A., Mulder C.J., Kraal G., and Bouma G. The effect of NOD2 activation on TLR2-mediated cytokine responses is dependent on activation dose and NOD2 genotype. Genes Immun 9 (2008) 274-278
140. Larche M. Regulatory T cells in allergy and asthma. Chest 132 (2007) 1007-1014
141. Akdis M., and Akdis C.A. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 119 (2007) 780-791
142. Prioult G., and Nagler-Anderson C. Mucosal immunity and allergic responses: lack of regulation and/or lack of microbial stimulation?. Immunol Rev 206 (2005) 204-218
143. Renz H., Blumer N., Virna S., Sel S., and Garn H. The immunological basis of the hygiene hypothesis. Chem Immunol Allergy 91 (2006) 30-48
144. Maggi L., Santarlasci V., Liotta F., Frosali F., Angeli R., Cosmi L., et al. Demonstration of circulating allergen-specific CD4+CD25highFoxp3+ T-regulatory cells in both nonatopic and atopic individuals. J Allergy Clin Immunol 120 (2007) 429-436
145. Horner A.A. Update on toll-like receptor ligands and allergy: implications for immunotherapy. Curr Allergy Asthma Rep 6 (2006) 395-401
146. Iwamura C., and Nakayama T. Toll-like receptors in the respiratory system: their roles in inflammation. Curr Allergy Asthma Rep 8 (2008) 7-13
147. Weigt H., Muhlradt P.F., Larbig M., Krug N., and Braun A. The Toll-like receptor-2/6 agonist macrophage-activating lipopeptide-2 cooperates with IFN-gamma to reverse the Th2 skew in an in vitro allergy model. J Immunol 172 (2004) 6080-6086
148. Vigouroux S., Yvon E., Biagi E., and Brenner M.K. Antigen-induced regulatory T cells. Blood 104 (2004) 26-33
149. Kuipers H., and Lambrecht B.N. Modification of dendritic cell function as a tool to prevent and treat allergic asthma. Vaccine 23 (2005) 4577-4588
150. Wagner H. Endogenous TLR ligands and autoimmunity. Adv Immunol 91 (2006) 159-173
151. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 6 (2006) 823-835
152. Krug A. Nucleic acid recognition receptors in autoimmunity. Handb Exp Pharmacol (2008) 129-151
153. Huang B., Zhao J., Unkeless J.C., Feng Z.H., and Xiong H. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 27 (2008) 218-224
154. Huang B., Zhao J., Li H., He K.L., Chen Y., Chen S.H., et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 65 (2005) 5009-5014
155. Harmey J.H., Bucana C.D., Lu W., Byrne A.M., McDonnell S., Lynch C., et al. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer 101 (2002) 415-422
156. Wang J.H., Manning B.J., Wu Q.D., Blankson S., Bouchier-Hayes D., and Redmond H.P. Endotoxin/lipopolysaccharide activates NF-kappa B and enhances tumor cell adhesion and invasion through a beta 1 integrin-dependent mechanism. J Immunol 170 (2003) 795-804
157. Wang R.F., Miyahara Y., and Wang H.Y. Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene 27 (2008) 181-189
158. Jurk M., and Vollmer J. Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation. BioDrugs 21 (2007) 387-401
159. Stoeter D., de Liguori Carino N., Marshall E., Poston G.J., and Wu A. Extensive necrosis of visceral melanoma metastases after immunotherapy. World J Surg Oncol 6 (2008) 30
160. Parkinson T. The future of toll-like receptor therapeutics. Curr Opin Mol Ther 10 (2008) 21-31
161. Killeen S.D., Wang J.H., Andrews E.J., and Redmond H.P. Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword?. Br J Cancer 95 (2006) 247-252
162. Spaner D.E., Foley R., Galipeau J., and Bramson J. Obstacles to effective Toll-like receptor agonist therapy for hematologic malignancies. Oncogene 27 (2008) 208-217
163. Melief C.J. Cancer immunotherapy by dendritic cells. Immunity 29 (2008) 372-383
164. Roses R.E., Xu M., Koski G.K., and Czerniecki B.J. Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer. Oncogene 27 (2008) 200-207
165. Bassukas I.D., Gamvroulia C., Zioga A., Nomikos K., and Fotika C. Cryosurgery during topical imiquimod: a successful combination modality for lentigo maligna. Int J Dermatol 47 (2008) 519-521
166. Hong-Geller E., Chaudhary A., and Lauer S. Targeting toll-like receptor signaling pathways for design of novel immune therapeutics. Curr Drug Discov Technol 5 (2008) 29-38
167. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5 (2006) 471-484
168. Agrawal S., and Kandimalla E.R. Synthetic agonists of Toll-like receptors 7, 8 and 9. Biochem Soc Trans 35 (2007) 1461-1467
169. Krieg A.M., and Vollmer J. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol Rev 220 (2007) 251-269
170. Raimondi G., Turner M.S., Thomson A.W., and Morel P.A. Naturally occurring regulatory T cells: recent insights in health and disease. Crit Rev Immunol 27 (2007) 61-95
171. Bauer S., Pigisch S., Hangel D., Kaufmann A., and Hamm S. Recognition of nucleic acid and nucleic acid analogs by Toll-like receptors 7, 8 and 9. Immunobiology 213 (2008) 315-328
172. Dayan C.M., and Wraith D.C. Preparing for first-in-man studies: the challenges for translational immunology post-TGN1412. Clin Exp Immunol 151 (2008) 231-234